Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
0(0%)
Results Posted
25%(2 trials)

Phase Distribution

Ph phase_3
3
30%
Ph phase_2
6
60%
Ph phase_1
1
10%

Phase Distribution

1

Early Stage

6

Mid Stage

3

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
6(60.0%)
Phase 3Large-scale testing
3(30.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Active(1)
Completed(8)
Terminated(1)

Detailed Status

Completed8
Not yet recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (10.0%)
Phase 26 (60.0%)
Phase 33 (30.0%)

Trials by Status

completed880%
not_yet_recruiting110%
withdrawn110%

Recent Activity

0 active trials
Showing 5 of 10
not_yet_recruitingphase_2

A Mechanistic Study on the Effect of HTD1801 Versus Placebo on Kidney Function in Patients With Type 2 Diabetes and Chronic Kidney Disease.

NCT07496177
completedphase_3

Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

NCT06415773
completedphase_3

Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes

NCT06350890
completedphase_3

Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

NCT06353347
completedphase_2

A POC and Dose-Ranging Study of HTD1801 in PSC Patients

NCT03333928
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07496177Phase 2

A Mechanistic Study on the Effect of HTD1801 Versus Placebo on Kidney Function in Patients With Type 2 Diabetes and Chronic Kidney Disease.

Not Yet Recruiting
NCT06415773Phase 3

Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

Completed
NCT06350890Phase 3

Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes

Completed
NCT06353347Phase 3

Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

Completed
NCT03333928Phase 2

A POC and Dose-Ranging Study of HTD1801 in PSC Patients

Completed
NCT05623189Phase 2

HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes

Completed
NCT06411275Phase 2

A Phase 2 Study of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Diet and Exercise

Completed
NCT03656744Phase 2

A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)

Completed
NCT03678480Phase 2

A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)

Withdrawn
NCT03099603Phase 1

A Study of HTD1801 in Healthy Subjects

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10